Supplemental information (Tables)

3 Months Ended

Nov. 30, 2023

Supplemental Cash Flow Elements [Abstract]

Schedule of Depreciation and Amortization Expense

The Company has recorded the following depreciation and amortization expense in the Consolidated Condensed Statements of Earnings (in millions):

	Three months ended November 30,
	2023		2022
Depreciation expense	$	376	$	336
Intangible assets amortization	240		159
Total depreciation and amortization expense	$	616	$	495

Restrictions on Cash and Cash Equivalents

The following represents a reconciliation of Cash and cash equivalents in the Consolidated Condensed Balance Sheets to total Cash, cash equivalents and restricted cash in the Consolidated Condensed Statements of Cash Flows as of November 30, 2023 and August 31, 2023, respectively (in millions):

	November 30, 2023		August 31, 2023
Cash and cash equivalents	$	784	$	739
Cash and cash equivalents - assets held for sale (included in other current assets)	—		24
Restricted cash - (included in other current and non-current assets)	62		93
Cash, cash equivalents and restricted cash	$	846	$	856

Schedule of Redeemable Noncontrolling Interest

The following represents a roll forward of the redeemable non-controlling interest in the Consolidated Condensed Balance Sheets (in millions):

	Three months ended November 30,
	2023		2022
Opening balance	$	167	$	1,042
Net loss attributable to Redeemable non-controlling interests	—		(22)
Redemption price adjustments and other 1	2		452
Reclassifications to Accrued expenses and other liabilities 2	—		(1,314)
Ending balance	$	169	$	157

1.Remeasurement of non-controlling interests, probable of redemption but not currently redeemable, to their redemption value, is recorded to Paid in capital in the Consolidated Condensed Balance Sheets. During the three months ended November 30, 2022, Shields and CareCentrix redeemable non-controlling interests were recorded to redemption value as the Company announced the acceleration of its plans for their full ownership.

2.The three months ended November 30, 2022 represents the reclassification of the Shields and CareCentrix redeemable non-controlling interests to Accrued expenses and other liabilities in the Consolidated Condensed Balance Sheets resulting from the Company's full acquisition of Shields and CareCentrix.

Schedule of Dividends Payable

Cash dividends per common share declared were as follows:

Quarter ended	2023		2022
November	$	0.4800	$	0.4800